Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial.

Karim Fizazi,Neal D Shore,Matthew Smith,Rodrigo Ramos,Robert Jones,Günter Niegisch,Egils Vjaters, Yuan Wang,Shankar Srinivasan,Toni Sarapohja,Frank Verholen

European journal of cancer (Oxford, England : 1990)（2023）

引用 0|浏览7

暂无评分

摘要

Darolutamide increased overall survival versus placebo, and incidences of most adverse events were similar between treatments in patients with ≤ 6 or >6 comorbidities and those taking ≤ 10 or >10 concomitant medications.

查看译文

关键词

Darolutamide, Non-metastatic castration-resistant prostate cancer, Comorbidities, Concomitant medications, Survival, Adverse events

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要